Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement

  • Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months, including patients with a more severe phenotype compared to previous studies
  • Two-thirds of patients (66.7%) were free of feeding support, an important indicator of stabilization/halting of disease progression
  • New interim Phase 3 STR1VE-EU data presented at WMS support the robust clinical evidence that …
/by
Sandoz launches its first RFID-tagged critical injectable medicines with Kit Check to optimize supply chain and automate restocking in US hospitals
  • First three Sandoz medicines labeled with RFID technology will be available in US hospitals starting in October, followed by several more through Q1 2021
  • Sandoz and Kit Check together provide comprehensive solutions to hospital customers to lower costs, reduce risks and treat patients safely and more efficiently
  • Advanced tracking technology streamlines inventory, workflow and auditing processes, further advancing Sandoz goal of being supplier of choice in hospitals

…

/by